Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Amyloid pathology in aDS individuals is linked to frontal‐predominant atrophy without clear hypometabolism.
Why it matters
This cross-sectional imaging study found progressive brain volume loss and metabolic decline along the Alzheimer's continuum in adults with Down syndrome. It compares how well MRI and FDG-PET detect disease stages but does not test any treatment, cure or prevention.
-
Lewy body dementias (LBD), comprising dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), are defined by misfolded α-synuclein aggregation.
Why it matters
In a very small proof-of-concept study using post-mortem cerebrospinal fluid from only six people, Raman spectroscopy combined with machine learning distinguished Lewy body dementia samples from controls within 24 hours. The authors state the sample size was very limited and the workflow strongly warrants validation in larger cohorts.
-
Genome-wide association studies (GWASs) have identified thousands of putative disease-causing variants with unknown regulatory effects.
Why it matters
This study introduced a pipeline for discovering splicing quantitative trait loci and applied it to identify significantly more sGenes with functional significance. The analysis implicated the variant rs528823 in Alzheimer disease, and antisense oligonucleotides blocking the implicated YBX3 binding site led to exon skipping in MS4A3.
-
Post-ischemic brain neurodegeneration with subsequent neuroinflammation is a major cause of mortality, permanent disability, and the development of Alzheimer’s disease type dementia in the absence of appropriate treatment.
Why it matters
This review examines how non-coding RNAs may interact with amyloid and tau to drive neuroinflammation after ischemic brain injury. It is a discussion of possible mechanisms, not evidence of a treatment or cure.
-
Altered β-amyloid (Aβ) homeostasis is a critical event triggering the shift from healthy aging to Alzheimer disease (AD) through the overproduction and impaired clearance of Aβ peptides.
Why it matters
This laboratory work identifies endothelin-converting enzyme 1 as an enzyme that degrades Aβ34 in cells and proposes a fragment as a possible measurable biomarker. It does not test any treatment in people and does not show an effect on preventing or curing Alzheimer's disease.
-
While previous studies have well established δ-opioid receptor (DOR)-mediated neuroprotection against Alzheimer's pathology, the underlying mechanisms remain poorly understood.
Why it matters
In mice with Alzheimer's-like pathology, activating the delta-opioid receptor reduced C1q levels, limited microglia-mediated synapse loss and improved cognitive performance. These are animal and cell results, so it is not yet known whether the same approach would work in people.
-
Tauopathies are a subgroup of neurodegenerative diseases pathologically typified as tau protein aggregate deposits in the brain, including Alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE).
Why it matters
Computer simulations showed that baicalein reduced the structural stability and β-sheet probability of AD-type and CTE-type tau protofibrils. This is a computational study only, so it does not show any benefit for treating, curing or preventing Alzheimer's disease.
-
With elevated HbA1c, greater LA-derived diol/epoxide ratios were associated with greater WMH volume (β [95% CI] = 0.565 [0.100, 1.030], p = 0.017), lower global BPF (β [95% CI] = -0.476 [-0.903, -0.048], p = 0.029), and poorer memory performance (β [95% CI] = -0.603 [-1.070, -0.136], p = 0.012), such that detrimental associations were observed only in T2DM.
Why it matters
In people with type 2 diabetes, higher HbA1c combined with greater linoleic acid-derived diol/epoxide ratios was associated with greater white matter hyperintensity volume, lower brain parenchymal fraction, and poorer memory. The authors suggest soluble epoxide hydrolase may be a potential therapeutic target in diabetes, but this is an association study and not a treatment trial.
-
NCs/CSVD-CN: AUC =0.900, 95% CI: 0.847-0.952.
Why it matters
This exploratory study found that combining the DTI-ALPS index, basal ganglia enlarged perivascular space counts, and choroid plexus volume may improve early diagnosis and subtype differentiation in cerebral small vessel disease-related cognitive impairment. It is a diagnostic study and does not test any treatment, cure, or prevention.
-
Research has shown that approximately 85 percent of the world's countries are not receiving enough omega-3s.
Why it matters
This report states that most countries have insufficient omega-3 intake, but it does not test any effect on Alzheimer's disease. It offers no evidence for treating, curing, or preventing Alzheimer's.
-
Intracellular aggregation and accumulation of protein is a hallmark of neurodegenerative diseases.
Why it matters
In mice co-expressing mutant tau and alpha-synuclein in neurons, researchers found increased phosphorylated tau, neuronal loss in the CA1 region, and increased astrocytes and microglia, along with decreased cognitive function. This is animal research on disease mechanisms and does not show a treatment or cure.
-
Our findings support a broader interpretation of TBK1-associated neurodegeneration and highlight the importance of multimodal diagnostic approaches that integrate molecular, genetic, imaging, and neuropathological tools.
Why it matters
In one patient with a TBK1 mutation, alpha-synuclein and tau pathology were both detected during life and multiple proteinopathies were confirmed after death. This single case report broadens the recognized spectrum of TBK1-related disease but does not provide a treatment or cure.
-
High Resolution Image Download MS PowerPoint Slide Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) form a continuous spectrum of aggressive neurodegenerative diseases affecting primarily motoneurons (MNs) and cortical frontotemporal neurons.
Why it matters
In laboratory cultures, a compound called GRT-X protected motor neurons exposed to toxic material from ALS/FTD astrocytes. This is early in-vitro work on ALS and frontotemporal dementia, not a treatment for Alzheimer's disease.
-
36/100
Aging is the greatest risk factor for learning and memory disorders; dementia prevalence significantly increases with age due to numerous molecular changes in the body.
Why it matters
In a transgenic mouse model, raising complement C3 caused learning and memory impairment with synaptic and neuronal loss, and antibody therapy targeting C3 in SAMP8 mice alleviated their memory deficits. These are animal results, and the authors suggest targeting C3 as a possible approach rather than a proven treatment.
-
Transactive response DNA binding protein-43 (TDP-43)-mediated pathology is a hallmark of devastating neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Why it matters
In mice, a single dose of a vectorized antibody targeting TDP-43 spread widely in the brain and was expressed for months, reducing pathological phospho-TDP-43 in neurons by 58% to 68% in a model of ALS/FTD. This is an early animal study showing a possible way to deliver antibody treatment to the brain with one dose.
-
Our results show that lecanemab exhibits high binding affinity to amyloid-β fibril structures that have a flexible N-terminus in common, as is the case for type I, type II and murine type III amyloid-β fibril polymorphs, which resemble or are identical to human structures observed in sporadic and familial cases of Alzheimer's disease, including a case with the Arctic (E22G) mutation.
Why it matters
In laboratory work with transgenic mouse-derived amyloid-beta fibrils, lecanemab bound strongly to fibril structures with a flexible N-terminus, resembling folds seen in sporadic and familial Alzheimer disease, but only weakly to fibrils with a fixed N-terminus. The authors suggest this may help explain the low incidence of ARIA-E with lecanemab, but these are structural binding findings, not evidence of clinical benefit.
-
Vascular dementia (VaD) is a leading cause of cognitive decline, closely associated with cerebrovascular endothelial cell (CEC) dysfunction, blood-brain barrier (BBB) disruption, and neuroinflammation.
Why it matters
In a mouse model of vascular dementia, the CD38 inhibitor 78c reduced white matter damage, improved blood flow, and decreased neuroinflammation and blood-brain barrier disruption. This is animal and cell research on vascular dementia, so it does not yet show a treatment for Alzheimer's disease in people.
-
Diagnosing Atypical Parkinsonian Syndromes (APS) may be challenging due to overlapping clinical features of Parkinson's disease (PD), and the lack of pathognomonic diagnostic tests.
Why it matters
This narrative review summarizes the current state of fluid biomarker research in atypical parkinsonian syndromes and their possible clinical use. It is about biomarkers for these syndromes, not about treating, curing or preventing Alzheimer's disease.
-
The volatile oil of ATR mitigates dementia through multiple pathways, including reducing abnormal protein aggregation, promoting neurogenesis, inhibiting neuronal apoptosis, regulating neurotransmitters, improving synaptic function, modulating autophagy, countering cellular stress, reducing neuroinflammation, and alleviating vascular risk factors.
Why it matters
This review describes how the volatile oil of Acori tatarinowii rhizoma may affect dementia through multiple pathways. The text states that further rigorous preclinical and clinical investigations are required, so no treatment or prevention benefit is established.
-
Down syndrome (DS), caused by trisomy of chromosome 21 (HSA21), is a complex condition associated with neurodevelopmental impairments and accelerated brain aging, often culminating in early-onset Alzheimer's disease (AD).
Why it matters
This review describes how mitochondrial imbalance in Down syndrome, driven partly by genes on chromosome 21, is thought to contribute to accelerated brain aging and Alzheimer-like pathology. It discusses emerging therapies targeting mitochondrial pathways but reports no tested treatment or outcome in patients.
-
We found that ICVIGF-1 administration protected working memory demonstrated as (1) reduced latency to reach the platform, and reduced swimming distance in trials 3 (p < 0.05) and 4 (p < 0.01) on days 45 and 90 post-injection and (2) a short-term (up to 45 days post-injection) enhancement of reference memory, manifested by a reduction in swimming distance and latency (p < 0.05).
Why it matters
In a rat model of sporadic Alzheimer's disease, central IGF-1 treatment improved working memory and short-term reference memory and reduced neuroinflammation and amyloid beta deposition. This is animal research, so it does not yet show that IGF-1 treats Alzheimer's disease in people.
-
The CGG repeat expansions in the 5'-UTR regions of certain genes have been implicated in various neurodegenerative and muscular disorders.
Why it matters
In laboratory and mouse work, the chaperone HSPB1 helped remove autophagy receptors from poly-glycine aggregates and restored autophagy, reducing poly-glycine-induced neurodegeneration. This is early mechanistic research on poly-glycine-associated disease, not a proven treatment, cure or prevention for Alzheimer's disease.
-
Human immunodeficiency virus (HIV) infections remain a significant public health burden globally with infected individuals at high risk for cognitive decline and memory loss even on combination antiretroviral therapy.
Why it matters
In human microglia cells in the laboratory, interaction between HIV gp120 and nicotine altered mitochondrial proteins and network properties and promoted release of amyloid precursor protein peptides. This is early cell research on HIV-related cognitive risk and does not show a treatment or prevention for Alzheimer's disease.
-
A major goal in Alzheimer disease (AD) research is the reduction of the abnormal tau burden.
Why it matters
In a mouse model of Alzheimer's disease with humanized hyperphosphorylated tau, the FDA-approved drug venetoclax, which blocks BCL2, markedly reduced the tau burden and neuroinflammation and kept treated mice robust until sacrifice. This is animal research, so it does not yet show that blocking BCL2 prevents tauopathy in people.
-
Die amyloide Selbstassemblierung von α‐Synuclein (αSyn) wird mit der Pathogenese der Parkinson‐Krankheit (PD) in Verbindung gebracht.
Why it matters
This laboratory study shows that macrocyclic peptides can inhibit the self-assembly and cross-nucleation of alpha-synuclein, a protein linked to Parkinson's disease, at nanomolar concentrations. The peptides also inhibited Aβ42-mediated cross-nucleation of alpha-synuclein, but this is early molecular work and no clinical testing in patients is reported.
From across this topic
9 of the 4,748 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Brain atrophy in 18 patients with Down syndrome: a CT study
- Accumulation of pathological tau species and memory loss in a conditional model of tauopathy
- Maternally inherited mitochondrial myopathy and myoclonic epilepsy
- Progressive inflammation-mediated neurodegeneration after traumatic brain or spinal cord injury
- Phase 2 study of zervimesine (CT1812) in participants with mild‐to‐moderate dementia with Lewy bodies (DLB)
- The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations
- Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease
- Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model
- Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides